Cargando…
PLOD3 contributes to HER-2 therapy resistance in gastric cancer through FoxO3/Survivin pathway
Human epidermal growth factor receptor 2 (HER-2), a famous therapeutic target for breast cancer, is also associated with an increased risk of recurrence and poor outcomes of other malignancies, including gastric cancer. Yet the mechanism of HER-2 therapy resistance remains controversial due to the h...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283410/ https://www.ncbi.nlm.nih.gov/pubmed/35835735 http://dx.doi.org/10.1038/s41420-022-01103-4 |